1061 results about "Benzoquinone" patented technology

The invention describes a pharmaceutical composition and method for treating cancer comprised of A) 2,3-dimethoxy-5-methyl-1,4-benzoquinone and / or B) at least one of wild yam root, teasel root, balm of gilead bud, bakuchi seed, dichroa root, kochia seed, kanta kari, bushy knotweed rhizome, arjun, babul chall bark, opopanax and bhumy amalaki; optionally one or more of frankincense, garcinia fruit, vitex, dragons blood, mace, sage and red sandalwood with at least c) one compound capable of maximizing oxidative mitochondrial function preferably riboflavin or vitamin B2 derivatives, FAD, FMN, 5-amino-6-(5′-phosphoribitylamino)uracil, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B1, lipoic acid, biotin, vitamin B6, vitamin B12, folate, niacin, vitamin C and pantothenate and / or d) at least one lactic acid dehydrogenase inhibitor (preferably 2′,3,4′5,7-pentahydroxyflavone) and optionally f) an alkalizing agent (aloe vera, chlorella, wheat grass, sodium or potassium bicarbonate, potassium) g) an antiproliferative herb (speranskia or goldenseal) and h) a pharmaceutically acceptable carrier.

A solid electrolyte capacitor having a solid electrolyte layer that is formed of a polymeric product layer of a polymerizable monomer. The polymeric product layer is doped with an organic sulfonic acid selected from the group consisting of an aromatic polysulfonic acid, an organic sulfonic acid having a hydroxy group, an organic sulfonic acid having a carboxyl group, an alicyclic sulfonic acid, and a benzoquinone sulfonic acid.

The invention describes a nutraceutical composition and method for preventing / treating cancer comprised of A) quinones (2,3-dimethoxy-5-methyl-1,4-benzoquinone, thymoquinone, tocopherolquinone) B) compounds capable of maximizing oxidative mitochondrial function preferably riboflavin, FAD, FMN, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B1, lipoic acid, biotin, vitamin B6, vitamin B12, folate, B3, C and pantothenate C) lactic acid dehydrogenase inhibitors; 2′,3,4′5,7-pentahydroxyflavone, epigallocatechin gallate, quercetin, citric acid, rosemary, black walnut, clove, nutmeg, licorice root, coriander, cinnamon, ginger root, myrrh gum and green tea D) alkalizing agents: aloe vera, chlorella, wheat grass, apple cider vinegar, burdock root, kudzu root, alfalfa, barley grass, spirulina, parsley leaf, calcium, magnesium, potassium or bicarbonate salts E) potent tumoricidal herbs; gromwell root, wild yam, beth root, teasel root, balm of gilead bud, frankincense, bakuchi seed, dichroa root, kochia seed, kanta kari, sweet myrrh, galbanum, garcinia fruit, mace, white sage and tumoricial plant derived constituents: gambogic acid, shikonin, diosmin or boswellic acid F) an antiproliferative herb (speranskia or goldenseal) and G) a pharmaceutically acceptable carrier.

The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog.

The present invention relates generally to treatment of muscle pain and / or fatigue and to methods for treatment of side effects of statin therapy. In particular, the invention relates to the use of certain substituted benzoquinones, e.g. Coenzymes Q, particularly Coenzyme Q10 (Q10), in therapy. The invention also relates to the use of Q10 in combinative therapy with other agents such as uridine, its biological precursors or salts, esters, tautomers or analogues thereof ("uridine related compounds"). The invention is also directed to compositions, uses and combination packs or kits related to the treatment methods. In a preferred aspect the invention relates to a method of treatment of one or more side effects of statin therapy comprising administering to a subject in need of such treatment an effective amount of uridine, one of its biological precursors or a salt, ester, tautomer or analogue thereof either simultaneously, sequentially or separately to administration of an effective amount of at least one compound of Formula (I).

The invention discloses a transition metal or an alloy nanocluster catalyst and preparation method and application thereof. The invention prepares a supported transition metal or an alloy nanoclustercatalyst by a new method in which a transition metal or an alloy nanocluster which is synthesized by an alkali-polyol method and stabilized by solvent and simple ions is supported on a carbon or oxidecarrier. The content of the transition metal or alloy nanocluster in the catalyst is 0.1-50wt%, and the particle size is 0.7-5nm. The transition metal or alloy nanocluster in the catalyst is distributed on the outer surface or in mesopores and macropores of the carrier material, and the atoms on the surface of the metal or alloy nanocluster have high availability. The catalyst has good catalyticperformance on the hydrogenation of 2,3,5-trimethylquinone, and the catalytic activity of the prepared Pt / Al2O3 and Pt / C supported metal nanocluster catalyst on the hydrogenation of the 2,3,5-trimethylquinone is much higher than that of the corresponding commercially available catalysts.

The present invention relates to methods and compositions comprising benzoquinones such as Duroquinone, for the use of treating, regulating or preventing a skin condition characterized by oxidative stress or a degenerative process. Methods of preventing, lightening or reducing the appearance of visible and / or tactile discontinuities of the skin resulting from skin pigmentation or skin aging are also disclosed.

A galvanic cell having a cathode, an anode, and an electrolyte. The cathode and anode each have vesicles, an electroactive species encapsulated into the vesicles, a conducting substrate, and functionalized tethers immobilizing the vesicles to the substrates. The electrolyte is in contact with both conducting substrates. At least some of the vesicles contain benzoquinone and / or hydroquinone.

The invention discloses a preparation method of the 9, 10-dihydro-9-oxa-10-phosphahenanthrene-10-oxide and the derivatives DDP, DDP-EG and DOPO-BQ. The invention has three steps to synthesize the DOPO: (1) preparation of CDOP, the O-phenylphenol (OPP) reacts with the Phosphorus trichloride (PCl3) with ZnCl2 as the catalyst. (2) purification of CDOP, vacuum distillation is carried out. (3) DOPO with high purity and yield is gained through the hydrolysis and crystallization. The preparation materials comprises the O-phenylphenol, the Phosphorus trichloride, the toluene, the alcohol, the deionized water, the itaconic acid, the ethylene glycol, the p-benzoquinone and the acetone. The invention simplifies the process conditions, improves the product purity with good production stability and repeatability. The purity of the product reaches over 99.0 per cent, the content of the chloride is below 50ppm, the OPP is about 0.01 per cent, the color is about 10 (10 per cent solution of acetone), the zinc-ion is less than 10ppm. The preparation method of the derivatives DDP, DDP-EG, DOPO-BQ is simple, good in stability and high in yield.

A polymerization inhibitor for inhibiting the polymerization of vinyl compounds, the polymerization inhibitor is a composition, including component A and component B. Wherein: Component A is one or a mixture of two or more of piperidine oxygen free radicals, nitrophenol or benzoquinone; Component B is diethylene glycol monomethyl ether, diethylene glycol dimethyl ether or diethylene glycol One or more mixtures of monobutyl ethers; in parts by weight, component A:component B=1:(0.5-2.0). The polymerization inhibitor may also include solvent dimethylformamide, toluene or xylene. Compared with the prior art, the advantage of the present invention is that when the solution-like polymerization inhibitor is prepared with a solvent, the amount of solvent is reduced, the concentration of effective components is increased, and the consumption of solvent is reduced; component A and component B are compounded and used After that, it has better polymerization inhibition performance, so that the ideal polymerization inhibition effect can be obtained by adding less polymerization inhibitor to the vinyl compound system.

The present invention is directed to a golf ball having at least one layer formed from a rubber composition comprising a base rubber, at least 0.05 parts by weight of a free radical initiator, per 100 parts of the base rubber, and at least 0.1 parts by weight of a benzoquinone, per 100 parts of the base rubber. The rubber composition may be present in any one or more of a core layer, a cover layer, or an intermediate layer.

The invention relates to a sealing adhesive strip for ribbed self-adhesive glass and a manufacturing method thereof. The sealing adhesive strip for the ribbed self-adhesive glass belongs to an elastic edge strip for sealing the edge of the glass of doors and windows, and comprises a built-in rubber strip rib and a butyl rubber sealant layer coated on the surface of the built-in rubber strip rib, wherein the butyl rubber sealant layer comprises the following raw material components in parts by weight: 30 parts of cross-linking butyl rubber, 5 parts of ethylene propylene diene rubber, 20 parts of polyisobutene of which the molecular weight is 40000, 40 parts of polyisobutene of which the molecular weight is 2400, 20 parts of amorphous state a-olefin copolymer, 30 parts of tackifying resin, 100 parts of filler, 5 parts of silicon dioxide, 10 parts of carbon black, 0.2 part of benzoquinone dioxime and 0.1 part of lead dioxide. The manufacturing method comprises the following steps: (1) banburying and kneading butyl rubber sealant; (2) coating and extruding. The invention provides the sealing adhesive strip for the ribbed self-adhesive glass, which has good low-temperature elasticity, simple construction process and low cost and is beneficial to environmental protection, a manufacturing method thereof. The sealing adhesive strip for the ribbed self-adhesive glass provided by the invention is suitable for sealing the glass of building doors and windows, curtain walls and automobile and ship doors and windows and the frame section bar of the glass.

A benzoquinone or hydroquinone for use in the topical treatment of a condition which is caused, exacerbated or transmitted by bacterial, in particular staphylococcal or propionibacterial, activity. The condition may be a skin or skin structure condition such as acne. The invention also provides the use of a benzo- or hydroquinone in the manufacture of a medicament for the treatment of such a condition.

A compound of the formula:wherein R1 represents a lower alkyl; R2 represents H, an optionally substituted alkyl or an optionally substituted alkenyl; R3 and R4 each represents an optionally substituted lower alkyl or a lower alkoxy, or R3 and R4 form, taken together, an optionally substituted butadienylene; and X1 and X2 each represents an optionally esterified or etherified hydroxy, or a salt thereof is useful for protecting cells from the cytotoxicity of beta-amyloid protein.

The invention relates to a 1,3,5,7-tetramethyl-8-triphenylamine base pyrrole methane-boron difluoride complex compound and a preparation method thereof, which belong to the technical field of organic synthesis. The existing photocatalysts have few varieties and low conversion rate, and the existing bodipy dye has low infrared fluorescent efficiency and small Stokes displacement. The invention provides the 1,3,5,7-tetramethyl-8-triphenylamine base pyrrole methane-boron difluoride complex compound. The preparation method comprises the steps that: 4-formoxyl tetramethyl and 2,4-dimethyl pyrrole are dissolved in organic solvents, trifluoroacetic acid or monoprop is used as catalysts, and a reaction system is formed; 2,3-dichloro-5,6-dicyan-1,4-para-benzoquinone with the same mol ratio as the 4-formoxyl tetramethyl is taken, is dissolved in the methylene dichloride and is added into the reaction system; and one of triethylamine, triisopropyl amine and N,N-diisopropylethylamine is added into the reaction system, boron trifluoride etherate is added under the ice bath, and final products are generated.

The preparation process of functional polyolefin resin includes electronic beam or gamma-ray pre-irradiation treatment of functional polyolefin resin; mechanical mixing of polyolefin resin after pre-treatment, functional monomer and electron donor reagent; and reacting extrusion for the polyolefin resin in molten state and functional monomer to produce grafting reaction. The polyolefin resin includes polyethylene, polypropylene, ethylene-propylene copolymer, ethylene-styrene copolymer, polystyrene, etc; the functional monomer is unsaturated organic acid or its derivative with amino group, isocyanate, hydroxyl group or other reactive functional group; and the electron donor reagent includes electron-rich compound with P, N, S or O element, p-benzoquinone, triphenyl phosphite, triphenyl phosphate, etc.

An alkyl- or halo-substituted benzoquinone, hydroquinone or mixture thereof, for use in the treatment of a periodontal disease, and / or for use in the treatment of a condition which is caused by, transmitted by or exacerbated by P. gingivalis or by biofilm formation by P. gingivalis.

Pharmaceutical formulation, its method of preparation, and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to treat horses infected with Sarcocystis protozoal infections.

The invention belongs to the field of catalysis and oxidization, and particularly discloses a method for preparing 1, 2-diketone by catalyzing and oxidizing alkynes. The method comprises the following steps: taking alkynes R1-C-C-R2 (acetylenic link exists between C and C) as a reaction substrate, taking one of TBHP, m-chloroperoxybenzoic acid and p-benzoquinone as a oxidant, taking one of dichloro (p-cymene) ruthenium (II) dimer, tri (triphenylphosphine) ruthenous chloride, ruthenium acetate, ruthenium dichlorophenyl (II) dimer, ruthenium trichloride, BINAP ruthenous chloride, dodecacarbonyltriruthenium and tricarbonyldichlororuthenium (II) dimer as a catalyst, taking one of iodine, iodine chloride, iodine bromide, potassium iodide, tetrabutyl ammonium iodide and potassium bromide as a cocatalyst, and taking 1, 4-dioxane as a solvent to react under 40 DEG C to 100 DEG C for 4 to 24 h to prepare the 1, 2-diketone. The method is economic, environmental-friendly and mild.

Benzoquinone compositions of enhanced solubility and bioavailability are described that contain at least one benzoquinone with at least one solubility-enhancing polymer. In one embodiment, the benzoquinone is coenzyme Q1O. Described methods to produce the bioenhanced products comprise dry blending and solvent spray drying. One aspect of the method includes the steps of providing a mixture comprising benzoquinone, a solubility-enhancing polymer and a solvent and removing the solvent to form amorphous benzoquinone. Products made by the invention's compositions and methods include pharmaceuticals, nutraceuticals, cosmetic, and personal care products for man and animal.

The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.

Silver-free, aqueous-based direct thermographic materials are designed to have image tone with near neutral density. Without the use of organic silver salts containing reducible silver ions, the image is formed using a color developing agent precursor that releases a color developing agent when heated to a temperature of at least 80° C., a combination of cyan, yellow and magenta dye-forming color couplers that provide cyan, yellow, and magenta dyes, and a substituted or unsubstituted benzoquinone as an oxidizing agent. No silver metal or silver ions are purposely added to these materials. This combination of components provides a means for controlling image tone without reliance upon conventional toning agents.

An acrylic urethane prepolymer composition and an unsaturated polyester resin composition to which the prepolymer has been added. The prepolymer composition includes an acrylic urethane prepolymer prepared by the reaction of diisocyanate, such as MDI, with an hydroxyl-containing acrylate monomer, such as a pentaerythritol triacrylate. The prepolymer composition contains a styrene monomer and an inhibitor, such as benzoquinone, to retard the reaction of the prepolymer and styrene monomer prior to the addition of the prepolymer composition into the polyester resin composition and a photoinitiator to promote the polymerization of the resin by exposure to radiant energy. The employment of the urethane prepolymer composition provides for the reduction in the amount of styrene monomer used in the unsaturated resin composition and also provides for improved chemical and physical properties of the photocured, unsaturated resin composition.

The present invention relates to a brexpiprazole preparation method, which comprises: (1) carrying out a condensation reaction of a compound represented by a formula III and a compound represented by a formula II in a solvent to prepare a compound represented by a formula IV; and (2) in a solvent, carrying out dehydrogenation on the compound represented by the formula IV with dichloro dicyano benzoquinone to obtain the brexpiprazole. With the method of the present invention, the reaction selectivity can be improved, the impurity generation can be reduced, the low yield problem caused by poor solubility of the key intermediate is avoided, and the total yield of the reaction is higher than 70.0%.

Antibodies are provided. For as example, an antibody capable of binding an artificial receptor which comprises a hydroquinone monolayer and is incapable of binding the artificial receptor when comprising a benzoquinone monolayer. Also provided are methods and systems using same for control delivery of a molecule-of-interest into a tissue.

The invention relates to a novel red BODIPY fluorescent dye with the chemical formula of C10+mH7+nBF2N2+xOy, wherein m, n, x and y are integers from 0 to 100. The preparation method comprises the following steps: dissolving pyrrole with substituent groups R1, R2 and R3 in an organic solution; adding ethyl glyoxylate together with nitrogen to the organic solution for a chemical reaction by using trifluoroacetic acid or toluenesulfonic acid as a catalyst; adding 2,3-dichloro-5,6-dicyano-1,4-benzoquinone oxidative dehydrogenation; and adding organic amine and a boron trifluoride diethyl ether solution for another reaction. After the reaction solution is concentrated, chromatography is performed with a silicagel column to obtain the fluorescent dye. The fluorescent dye can be used for cell imaging, fluorescent probe or laser dye. The fluorescent dye has the advantages that the ultraviolet-visible absorption spectrum and the fluorescence emission spectrum of the fluorescent dye are narrow; fluorescent quanta has high efficiency and good light stability; and the fluorescent dye has simple molecular structure and can be synthesized easily, so as to facilitate popularization and application.

The invention discloses a p-n-type Bi2O3 / BiPO4 heterostructure visible light-response photocatalytic film material and a preparation method thereof. The preparation method comprises the following steps of dissolving a glycol solution containing Bi<3+> and PO4<3-> into water, carrying out precipitation, washing, drying, constant-temperature calcinations and grinding to obtain white BiPO4 powder, dissolving KI and the white BiPO4 powder into acetone to obtain an electrolyte solution, carrying out electrophoretic deposition on a conductive substrate in the electrolyte solution to obtain a precursor BiPO4 film, dissolving KI, Bi(NO3)3 and p-benzoquinone into water, adjusting a pH value to obtain a Bi2O3 electrodeposition solution, carrying out electrodeposition on the precursor BiPO4 film, a platinum sheet, an Ag / AgCl electrode and the Bi2O3 electrodeposition solution, carrying out dry and carrying out calcination. The composite photocatalyst has high photocatalytic activity and stability and has good electrocatalysis degradation effects.

The invention discloses a method for utilizing a molecularly imprinted electrochemical sensor to detect trace gibberellin A3. The method comprises the following steps of: o-phenylenediamine is taken as a function monomer, and gibberellin is adopted as a moldboard molecule to obtain a gibberellin A3 molecularly imprinted film through polymerization of mitallic electrode surface electricity; in the hydrogen peroxide-hydroquinone bottom solution with the pH of 7.4, the polyamide-amine arborization macromolecule complexed with a ferric ion can carry out catalyzing degradation on the hydrogen peroxide under energization; and the gibberellin A3 in the sample is utilized to replace functionalized arborization macromolecule gibberellin A3, so that the reduction strength of p-benzoquinone to hydroquinone is increased, and a method for detecting the gibberellin A3 is established. When the gibberellin A3 is in concentration range of 3*10-7mol / L-6*10-9mol / L, the lifting degree of an electrochemistry signal and the concentration of the gibberellin A3 is of a good linear relationship, and the method detection limit is 2.0*10-9 mol / L. The method provided by the invention improves the detective sensitivity and selectivity, and the detection of the light concentration gibberellin A3 is easy to be automated.

The invention discloses an aromatic condensed ring quinones compound positive pole material for a one-class lithium secondary battery. The compound is a quinones compound which takes benzoquinone or isobenzoquinone with an aromatic condensed ring structure as a electrochemical oxidation reduction reaction locus, and the compound comprises an aromatic condensed ring benzoquinone derivative and an aromatic condensed ring isobenzoquinone derivative; the compound can join in pole preparation in a molecular crystal or polymer mode; in the polymer mode, corresponding structural units are directly connected through C-C bonds or connected through S atoms; and the benzoquinone / isobenzoquinone which is stabilized through an aromatic (hetero) condensed ring is used as the electrochemical oxidation reduction reaction locus and is compounded with conductive carbon in the molecular crystal or polymer mode so as to prepare the pole. The material has the advantages that the positive pole material has high energy density, rate power density and circulation stability, 86% of the initial capacity can be still maintained after being circulated for 50 cycles, so that the material can be probably applied to the next generation of environmental-friendliness energy storage batteries with high energy and high power.